Here, we systematically assessed the in vitro inhibitory effects of three selected ALK inhibitors, namely lorlatinib, crizotinib, and brigatinib, on hOCT1 to 3- and hMATE1/2-K-mediated transport of mIBG, which has a high chance of being used in combination with ALK inhibitors to diagnose and treat NBL and other neuroendocrine cancers [12]. This evidence concerns the gene ALK and neuroendocrine carcinoma.